Placebo-controlled randomized double-blind international and multicentric trial of 4th phase that should prove efficacy of influenza vaccine Fluarix administrated intramuscularly to adults
Abstract
This work tries to evaluate the efficacy, reactogenity, safety, and immunogenicity of GSK Biologicals' influenza vaccine Fluarix administrated intramuscularly in one dose scheme in healthy adults aged 18 - 64. The efficacy was followed on the population of 7652 subjects in Czech Republic and Finland during 2006/2007 influenza season.
According to obtained results the author demonstrates high vaccine efficacy, excellent immunogenicity, low reactogenity and high vaccine safety.